CI-980 in advanced melanoma and hormone refractory prostate cancer.

Abstract

INTRODUCTION:

CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines.

METHODS:

13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks.

RESULTS:

No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively.

CONCLUSIONS:

CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

• Authors: C W Ryan, K L Shulman, J M Richards, J W Kugler, J A Sosman, R H Ansari, E E Vokes, N J Vogelzang
• Journal: Investigational new drugs (Invest New Drugs) Vol. 18 Issue 2 Pg. 187-91 (May 2000) ISSN: 0167-6997 [Print] United States
• PMID: 10857996 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Carbamates
• Pyrazines
• Pyridines
• canertinib dihydrochloride

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carbamates (adverse effects, therapeutic use)
• Drug Resistance, Neoplasm
• Female
• Humans
• Male
• Melanoma (drug therapy)
• Middle Aged
• Prostatic Neoplasms (drug therapy)
• Pyrazines (adverse effects, therapeutic use)
• Pyridines (adverse effects, therapeutic use)